Novel molecular designs unlock therapeutic potential of nicotine receptors

To address the major health threat posed by smoking-related diseases, there is a challenge to find smoking cessation therapies that are both low cost (and so widely-accessible) and that support smokers effectively to manage and then conquer their addiction. Computer simulations of smoking cessation drug cytisine (Tabex) and novel derivatives bound to nicotinic receptors have helped to understand how these drugs function. This work was carried out as part of a multidisciplinary project in partnership with colleagues from the universities of Bath, Oxford Brookes and Milan, involving organic and computational chemists, neuroscientists and pharmacologists.

For more information see:

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s